Literature DB >> 17603768

Carcinoma of the tongue and bulbar-onset amyotrophic lateral sclerosis: unusual differential diagnosis.

P Volanti1, M Mannino, T Piccoli, V La Bella.   

Abstract

We present a 72-year-old woman with progressive dysphagia, dysarthria and tongue palsy who was initially diagnosed with bulbar-onset amyotrophic lateral sclerosis (ALS). However, the absence of atrophy or fasciculations in the tongue, as in other voluntary muscles, and the lack of reproducible neurophysiological evidence of denervation, prompted a revision of the diagnostic work-up, which eventually led to the discovery of a carcinoma of the tongue. This case report describes a relatively rare type of oropharyngeal carcinoma that, in its early stage, resembled a bulbar-onset ALS. This differential diagnosis is unusual, and it was fostered by the persistent lack of atrophy of the tongue and the absence of spreading of signs and symptoms of motor neuron degeneration.

Entities:  

Mesh:

Year:  2007        PMID: 17603768     DOI: 10.1007/s10072-007-0809-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  13 in total

Review 1.  The role of electromyography (EMG) in the diagnosis of ALS.

Authors:  M Tröger; R Dengler
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-06

Review 2.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

Review 3.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

4.  Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?

Authors:  E Househam; M Swash
Journal:  J Neurol Sci       Date:  2000-11-01       Impact factor: 3.181

5.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

6.  An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.

Authors:  Bryan J Traynor; Michael Alexander; Bernie Corr; Eithne Frost; Orla Hardiman
Journal:  J Neurol       Date:  2003-04       Impact factor: 4.849

7.  Multidisciplinary ALS care improves quality of life in patients with ALS.

Authors:  J P Van den Berg; S Kalmijn; E Lindeman; J H Veldink; M de Visser; M M Van der Graaff; J H J Wokke; L H Van den Berg
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

8.  Twelfth-nerve palsy. Analysis of 100 cases.

Authors:  J R Keane
Journal:  Arch Neurol       Date:  1996-06

Review 9.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  R G Miller; J D Mitchell; M Lyon; D H Moore
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2003-09

10.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.

Authors:  B J Traynor; M Alexander; B Corr; E Frost; O Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

View more
  2 in total

1.  Carcinoma of the tongue mimicking bulbar amyotrophic lateral sclerosis.

Authors:  Monica Bandettini di Poggio; Davide Brogi; Alessandro Leonardi; Matteo Pizzorno; Guido Schenone; Giovanni Luigi Mancardi; Elisabetta Capello; Angelo Schenone
Journal:  Neurol Sci       Date:  2008-04       Impact factor: 3.307

Review 2.  Clinical Measures of Bulbar Dysfunction in ALS.

Authors:  Yana Yunusova; Emily K Plowman; Jordan R Green; Carolina Barnett; Peter Bede
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.